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Abstract 
 
The cannabinoid partial agonist BAY 59-3704 has been identified as an attractive target to 
explore structure-activity relationships at cannabinoid receptors for the development of a 
therapeutic agent for psychostimulant addiction. This thesis will describe the studies associated 
with the optimization of a palladium-catalyzed oxidative ring closure reaction for the synthesis 
of dibenzofuran analogues from substituted diaryl ethers. These dibenzofurans are viewed as 
rigid analogues of BAY 59-3704 and will provide useful information about molecular 
interactions at cannabinoid receptors. The scope and limitations of the palladium-catalyzed 
oxidative ring closure reaction as it relates to the synthesis of the target dibenzofuran analogues 
will be presented. 
 
 
 
Key Words: cannabinoid, dibenzofuran, diaryl either, palladium, oxidative ring closure. 	  	  	  	  	  	  	  
 
 
 
 
 
7 
Introduction 
 Problems of Drug Addiction 
In 2009, approximately 21.8 million people aged 12 or older were identified as illicit drug 
users according to the National Household Survey on Drug Use and Health.1 Of those surveyed, 
the abuse of psychostimulants, including methamphetamine and cocaine, contributed 
significantly (39%) to the overall national profile of illicit drug use. Today, there has been little 
deviation from this level of psychostimulant abuse. Unfortunately, there currently are no 
effective pharmacotherapies for the treatment of either cocaine or methamphetamine addiction.  
In lieu of the lack of any clinically available medications for these widely abused illicit drugs, 
the proposed study to develop new medications is highly significant.  
The development of new medications for the treatment of illicit drug abuse is extremely 
important to the welfare of the United States and the health of its citizens. There is substantial 
evidence indicating that the cannabinoid system can modulate dopaminergic transmission 
indirectly and thus mediate the effects of psychostimulants on the reward and pleasure circuitry 
of the brain.2-5 Studies have shown that the cannabinoid agonist WIN55,212-2 (Figure 1) 
attenuates the rewarding actions of cocaine and decreased the reinforcing actions of cocaine.6,7 In 
addition, the cannabinoid antagonist SR141716A has been shown to modulate the rewarding 
effects of drugs like opiates, cocaine and nicotine.8 More recently, the cannabinoid antagonist 
AM251 has been reported to reduce methamphetamine self-administration in rodents and 
primates.9 However, current antagonists act as inverse agonists at the cannabinoid receptor and 
therefore produce side effects that have limited their clinical usefulness. Thus, the development 
0and investigation of novel cannabinoid based medications (low efficacy agonists) is highly 
significant since the availability of these compounds will aid in identifying new treatment 
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strategies for psychostimulant abuse and dependence. Compounds identified in this study will be 
made available to the NIDA Addiction Treatment Discovery Program as well as to other 
researchers to evaluate the therapeutic potential for the treatment of drug addiction.  
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Figure 1. Cannabinoids that have been shown to effect psychostimulant activity 
 
Cannabinoid Receptors 	  
       
 
Figure 2. Cannabinoid Receptors 
 
 The principal psychoactive component of marijuana is Δ9-tetrahydrocannibinol (Δ9-
THC).10 The effects of Δ9-THC are mediated by occupation of receptors located throughout the 
body. Currently two subtypes of transmembrane G-protein coupled receptors have been reported 
(CB1 and CB2).11-14 The CB1 receptors are found in the CNS with high density in the 
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cerebellum, hippocampus and striatum.15 In addition, CB1 receptors exist in a variety of other 
organs that include the heart, small intestine, vas deferens, testis and uterus.16 CB2 receptors are 
primarily in organs associated with the immune system (tonsils, spleen and immune cells).17 
However, a recent report has described CB2 receptors present in the CNS, although at a much 
smaller concentration than CB1 receptors.17b While both CB1 and CB2 receptors have been 
cloned and the amino acid sequences known, the three-dimensional structures of the receptors 
and structures of the binding sites have yet to be established. To date, characterization of these 
receptor subtypes has relied upon ligand–receptor interactions.18-21 
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 The CB1 receptor is pharmacologically activated upon small molecule occupation of the 
binding site. Four classes of ligands typify CB1 receptor agonists (Figure 2).9 These include the 
classical cannabinoids typified by Δ9-THC and HU-210; the non-classical cannabinoids [e.g. 
CP55,940 , BAY38-727122] the aminoindoles [e.g. WIN55,212-2]; and the endogenous 
cannabinoids [e.g. anandamide].19 These ligands typically exhibit nanomolar affinity for CB1 
receptors and are generally non-selective for CB1 over CB2 receptor subtypes. Of these, 
anandamide has been reported to exhibit a significant differential in binding affinities between 
the two subtypes [Ki = 61 nM (CB1) and Ki = 1930 nM (CB2).23 CB1 receptor agonists inhibit 
cAMP production through inhibition of adenylyl cyclase,24 inhibit Ca+2 influx25, activate K+ 
channels26 and activate MAP kinase pathways.27 CB1 receptor agonists have been shown to 
increase intracellular dopamine levels in brain (striatum) similar to cocaine.28-30 It is believed that 
CB1 agonist modulation of dopamine levels in the CNS is responsible in part for the abuse 
liability observed for cannabinoid agonists.3,4,31  
Among known CB agonists, several compounds have been reported to exhibit low 
efficacy agonist profiles in vitro and in vivo. These partial agonists include Δ9-THC32, BAY59-
3704,33-35 CB-25 and CB-52 (Figure 3)36,37 All of these CB ligands exhibited modest binding 
affinity at CB1 and CB2 receptor subtypes (Ki values 30-50 nM).  Only CB-25 exhibited CB1 
selective low nanomolar affinity (Ki = 5 nM) at CB1 receptors. These compounds stimulated 
[35S]GTPgS binding, but were significantly less efficacious than the full agonists CP-55,940, 
BAY 38-7271 or WIN 55,212-2 and hence have been designated as partial agonists. It is 
noteworthy that BAY 59-3074 exhibited no abuse potential and did not produce withdrawal 
behavioral effects when daily doses were stopped after two weeks.34 The phenols CB-25 and 
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CB-52 were characterized as partial agonists at CB1 receptor subtypes and neutral antagonists at 
CB2 receptor subtypes.36,37 
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Figure 4. Low Efficacy Cannabinoid Agonists 
 
Novel CB1 Receptor Low Efficacy Cannabinoid Agonists 
 The development of new CB1 selective, low efficacy agonists as a pharmacotherapy for 
cocaine and/or methamphetamine addiction to our knowledge has not been explored. 
Cannabinoid full agonists and antagonists clearly have limitations as therapeutics due to 
deleterious side effects. However a CB1 selective low efficacy agonist would likely have 
diminished side effects relative to a full agonist or antagonist, while effectively modulating 
psychostimulant mediated dopaminergic activity. The development of a low efficacy CB1 
agonist for use as a substitution therapy for cocaine and/or methamphetamine is highly 
innovative. This approach has been successfully used for decades for opioid addiction. The low 
efficacy opioid agonist methadone remains one of the leading treatment strategies for heroin 
addiction.  
 Recent studies have suggested that in a controlled environment with compliant patients, 
agonist-based approaches may be more successful for maintenance and withdrawal symptoms 
than antagonist based approaches, which are plagued with potential side effects.56  Therefore, it is 
attractive to develop new psychostimulant medications from low efficacy cannabinoid agonists 
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rather than from known cannabinoid antagonist/inverse agonists. It is envisaged that such an 
approach would minimize the potential for adverse side effects and provide compounds with 
better safety profiles. 
 
Novel CB1 Receptor Ligands. 
 The BAY59-3704 diaryl ether scaffold is ideally suited to explore this hypothesis in that 
it already has been established that specific structural modification of BAY59-3704 can lead to a 
full agonist profile [BAY 38-7271].22 Therefore it is reasonable to believe that an alternative 
modification of the biaryl ether system would lead to diminished efficacy and a CB1 selective 
low efficacy agonist profile. This complete spectrum of pharmacological activity within a single 
class of molecular scaffolds is well established among opioid receptor ligands but has not been 
fully realized in a cannabinoid system. Clearly the development of such a class of full spectrum 
CB ligands would not only be highly innovative but also highly desirable by providing tools to 
study the fundamentals of receptor activation.  
 While BAY59-3704 has been known for several years, it has received limited attention33-
35 and has not been studied as a treatment for drug abuse. Presumably this is due to low CB1 
selectivity and limited availability of the drug.  A systematic investigation of the structure-
activity relationships of the target diaryl ethers and related derivatives will provide significant 
insight into important structural features associated with high potency and low efficacy. 
Although, some structure-activity studies have been reported in the patent literature,33 there 
remains a significant amount of SAR to investigate. This will aid in the development of a CB1 
pharmacophore that can be used to design novel compounds targeted as low efficacy agonists. In 
addition, hybrid structures of known low efficacy CB1 ligands have not been explored 
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previously. As such, additional innovation can be gleaned from the novel hybrid structures that 
will be developed during this investigation from BAY59-3704 and CB-25.  
 
Previous Research 
 An efficient, safe, and scalable method for the preparation of phloroglucinol monoaryl 
ethers has been developed by the Trudell Group to prepare novel diaryl ether molecular scaffolds 
similar to that of BAY59-3704.3 A variety of novel functionalized phorologlucinol monoaryl 
ethers were synthesized using a two-step procedure (Scheme 1). Target ethers were synthesized 
by coupling electron-deficient aryl fluorides with 3,5-dimethoxyphenol via nucleophilic aromatic 
substitution (SNAr) in N-methylpyrrolidone (NMP) and KOH. The uncatalyzed aryl coupling 
reaction was chemoselective and furnished the diaryl ethers cleanly with few side reactions. 
Subsequent boron tribromide-mediated demethylation gave a series of phloroglucinol monoaryl 
ethers in good overall yields.3 Monoalkylation of the phenol group then furnished a series of 
alkyl phloroglucinol monoaryl ethers for biological study at cannabinoid receptors. 
Scheme 1. Synthesis of phloroglucinol monoaryl ethers and alkyl phloroglucinol monoaryl 
ethers  
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From these studies, the phloroglucinol derivative AMS-167 (Figure 4) exhibited exceptionally 
high affinity for CB1 receptors (Ki = 1.2 nM).  The improved binding affinity of the diaryl ether 
AMS-167 over BAY 59-3704 prompted us to use AMS-167 as our lead compound the 
development of new cannabinoid receptor ligands.  Since it had already been shown that specific 
structural modification of the BAY59-3704 diaryl ether scaffold could lead to a full agonist 
profile [BAY 38-7271],22  it was reasonable to believe that an alternative modification of the 
biaryl ether system would lead to diminished efficacy and a CB1 selective low efficacy agonist 
profile.  While BAY59-3704 has been known for several years, it has received limited attention33-
35 and has not been studied as a treatment for drug abuse. Presumably this is due to low CB1 
selectivity and limited availability of the drug. The design of novel CB1 receptor ligands will be 
guided by the structures of lead compound AMS-167. The diaryl ether derivative AMS-167 will 
serves as the template for the investigation of the SAR of these potentially potent ligands.  	  
F3C
CN
O
OH
O
AMS-167
O
CN
F3C O
S
O O
CF3
BAY 59-3074 	  
Figure	  5.	  AMS-­‐167	  and	  BAY-­‐3074	  
 
Rigid Analogues of AMS-167 
As part of a study aimed at evaluating the structure-activity relationships of AMS-167 it was of 
interest to prepare a rigid analogue of AMS-167. A rigid analogue would provide important 
conformational information about how AMS-167 interacts with the cannabinoid receptor. To this 
end, the dibenzofuran analogue of AMS-167 was identified as a synthetic target (Figure 5). By 
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forming a covalent carbon-carbon bond between the two aryl rings of AMS-167, the 
dibenzofuran derivative would have much less conformational freedom. Hence the dibenzofuran 
system would provide important information regarding the relative positions of the functional 
groups and the importance for binding at cannabinoid receptors. 
 
Synthetic Approach: Palladium Catalyzed Oxidative Ring Closure: 
 In a recent article82 published in the Journal of Organic Chemistry, a new reaction for  
intramolecular palladium(II)-catalyzed oxidative carbon-carbon bond formation was described. 
In this paper, diaryl ethers and diaryl amines were readily converted into dibenzofuran and 
carbazole dervivative via intramolecular palladium(II)-catalyzed oxidative ring closure (Figure 
6) In this study the authors showed that the use of pivalic acid as the reaction solvent, instead of 
acetic acid, afforded greater reproducibility, higher yields, and broader scope of substrates.82 
Based upon this study, the intramolecular palladium(II)-catalyzed oxidative ring closing reaction 
seemed like and ideal method for the preparation of the dibenzofuran molecular scaffold that 
would be need for the synthesis of a rigid analogue of AMS-167 (Figure 6).  
 
X
Pd(OAc)2
PivOH, air
X = O, NH
X Y
X
X = O, NH
X Y
up tp 95% yield  
Figure 6. Intramolecular palladium (II)-catalyzed oxidative ring closing reaction 
 
As illustrated by retrosynthetic analysis in Scheme 2, the intramolecular palladium(II)-catalyzed 
oxidative ring closing reaction could be used to generate the appropriately substituted 
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dibenzofuran from the corresponding diaryl ether.  To this end, the focus of this research was to 
explore the potential of the intramolecular palladium(II)-catalyzed oxidative ring closing reaction 
for the construction of the dibenzofuran. This Honors Thesis describes the studies associated 
with the optimization of the palladium-catalyzed oxidative ring closure reaction for the synthesis 
of dibenzofuran. In addition the thesis describes the scope and limitations of the palladium-
catalyzed oxidative ring closure reaction as it relates to the synthesis of dibenzofuran analogues. 
 
Scheme 2. Retrosynthetic analysis of rigid analogue of AMS-167. 
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Results and Discussion 
Synthesis of 2-(3,5-Dimethoxyphenoxy)-6-(trifluoromethyl)-benzonitrile  
Prior to beginning of the study on the palladium-catalyzed oxidative ring closure reaction it  was 
necessary to synthesize the diaryl ether precusor, 2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)-
benzonitrile (1). As illustrated in Scheme 3, the diaryl ether 1, was prepared from 3,5-
dimethoxyphenol and 2-fluoro-6-(trifluoromethyl)-benzonitrile using reaction conditions 
previously developed in our laboratories.81 This furnished the diaryl ether 1 in 99% yield and in 
high purity. 
 
Scheme 3. 2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)-benzonitrile (1) 
 
F3C
CN
F HO
O
O
CsCO3
NMP, 50°C F3C
CN
O
O
O
+
1 (99% yield)  
 
With the diaryl ether 1 in hand, it was essential to characterize the compound by 1H NMR in 
order to use NMR to evaluate the success of the palladium-catalyzed oxidative ring closure 
reaction. As illustrated in Figure 7, the protons H5 and H2’ of 1, will be absent in the 
dibenzofuran 2. Therefore it should be possible to monitor these signals to determine the 
progress of the reaction. 
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F3C
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Figure 7. Comparison of diphenyl ether 1 with benzofuran 2.  
The 1H NMR spectrum of 1, is shown in Figure 8. Based upon the shielding effects of the 
substituents and the spin-spin splitting, the signal for H5 was assigned to the doublet at 7.15 
ppm. Alternatively, the signal for H2’ was assigned as the singlet at 6.26 ppm. 
 
 
Figure 8. 1H NMR Spectrum of 2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)-benzonitrile (1)  
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Figure 9. 13C NMR Spectrum of 2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)-benzonitrile (1) 
 
Optimization of the palladium-catalyzed oxidative ring closure reaction  
As illustrated in Scheme 4, optimization of the palladium-catalyzed oxidative ring closure 
involves the identification of the optimum reagent concentrations, reaction temperature and 
reaction time. The chemical reagents involved in the transformation includes: diaryl ether 1,  
palladium(II)-acetate [Pd(OAc)2], pivalic acid [(CH3)3CO2H], an oxygen source (air or O2)  and 
potassium carbonate (K2CO3). In an effort to optimize the conditions for the palladium-catalyzed 
oxidative ring closure reaction of 1, a series of experiments were performed using varied reaction 
conditions.  
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Scheme 4. Palladium-catalyzed oxidative ring closure reaction of 1. 
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PivOH
O2
K2CO3, 
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O
CN
F3C O
O
O
CN
F3C O
O
1 2
 
As summarized in Table 1, the first study examined the effect of catalyst loading on the 
efficiency of the reaction. In this study the amount of palladium acetate was varied relative to the 
amount of the diaryl ether 1. All other reagents and conditions were maintained at similar levels.  
 
Table 1. Effect of Catalyst Loading 
 
 
 
 
From this study it was clear that catalyst loading had a significant effect on the ring closure 
reaction. As a catalyst, Pd(OAc)2 was most effective for ring closure when present in 20 mol% to 
25 mol%. This afforded good conversion of the diaryl ether 1 into the dibenzofuran 2. Clearly 
high catalyst loading was necessary to obtain high conversion of 1 into 2. Low catalyst loading 
(5 -10 mol %) gave low conversion of 1 into 2. It is noteworthy, that the palladium chloride 
Entry 1 
(mmol) 
Catalyst 
(mol %) 
K2CO3 
mol% 
Oxygen 
Source 
 
Pivalic 
Acid  
(gm) 
Temp 
(°C) 
Time 
(hrs) 
Conv. 
(%) 
SA-99 0.5 Pd(OAc)2 
(5%) 
10 air 0.45 120 72 31 
SA-98 0.5 Pd(OAc)2 
(10%) 
10 air 0.45 120 72 <1 
SA-102 0.5 Pd(OAc)2 
(20%) 
10 air 0.9 120 72 72 
SA-104 0.5 Pd(OAc)2 
(25%) 
10 air 1.1 120 72 81 
SA-107 0.5 PdCl2 
(20%) 
20 air 1.0 120 72 < 1 
 
 
21 
(entry SA-107) gave poor conversion at high catalyst loading despite the efficiency observed for 
palladium acetate. In summary the results of this catalyst loading study demonstrate that 
Pd(OAc)2 is an effective catalyst for the ring closure reaction at high loading concentrations. 
However, Pd(OAc)2 was inefficient at low loading and PdCl2 was unreactive in this system. 
 
 
NMR Analysis of Dibenzofuran 2  
 
 
 
 
Figure 10:1H NMR Spectrum of  7,9-dimethoxy-2-(trifluoromethyl)dibenzofuran-carbonitrile(2) 
 
The 1H NMR spectrum of 2, is shown in Figure 10. Based upon the shielding effects of the 
substituent and the spin-spin splitting, the addition of carbon-carbon bond results in electron 
deficient ring system and the activating O-methyl groups are now asymmetrical, shows two 
peaks at 4.08 and 3.93 ppm.  Peaks are shifted down field and we see two doublets at 7.68 ppm 
and 8.22 ppm. 
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Effect of Surface Area 
Table 2 summarizes the effect that reaction media surface area can play in product formation. 
Since the reaction progress is dependent upon the reactants exposure to air it was of interest to 
see if a larger reaction surface area would effect the conversion of 1 into 2. In this study a broad 
diameter 20 ml reaction vial was employed instead of a narrow 10 ml reaction tube. Using the 
optimized catalyst loading of 25 mol% it was found that increasing the surface area of the 
reaction media led to increased reaction times and lower conversion (39%) into product (entry 
SA-106). The addition of Pd(OAc)2 over the course of 12 days did lead to better conversion 
(66%) but did not improve the overall conversion relative to the reaction tube. 
 
Table 2. Use of a Reaction Vial 
 
*V = vial 
 
While the difference in reaction efficiency between the small volume and large volume reaction 
vessels is not fully understood at this time, it seems that the effect may be related to cooling 
efficiency of the glass vessels. The narrow reaction tube seemed to keep the solvent from 
evaporating away from the reaction mixture. The broader diameter reaction vial seemed to allow 
the solvent to vaporize into the air. This would lead to a significant reduction in volume, which 
in turn may have led to thermal decomposition of the catalyst. This would be consistent with the 
 
 
Entry 
 
1 
(mmol) 
 
Pd(OAc)2 
(mol %) 
 
K2CO3 
mol% 
 
Oxygen 
Source 
Pivalic 
Acid 
(gm) 
 
Temp 
(oC) 
 
Time 
(hrs) 
 
Conv. 
(%) 
SA-106 
(V)* 
0.5 25 25 air 2 120 72 39 
SA-111 
(V)* 
2.1 3 ×  25 3 ×  25 air 3 ×  1 120 12 
(days) 
66 
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fact that addition of second and third portion of Pd(OAc)2 was necessary to move the reaction 
forward. 
 
Effects of Microwave Heating 
 
Table 3 shows the effects of microwave heating. Attempts to decrease the reaction time and to 
make the reaction more environmentally friendly (Green Chemistry) were unsuccessful. The 
results from these experiments indicate that microwave heating is not applicable for this reaction 
The high localized heat results in decomposition of catalyst. The low conversion to product is 
presumably due to failure to regenerate the catalyst, which is essential for this reaction. 
 
Table 3. Effects of Microwave Heating 
 
 
Effect of Oxygen Source  
As summarized in Table 4, it was determined that air was most effective source of oxygen for the 
palladium catalyzed reaction. The addition of alternative oxygen sources had a negative effect on 
product formation.  
 
 
 
 
 
Entry 
 
1 
(mmol) 
 
Pd(OAc)2 
(mol %) 
 
K2CO3 
(mol%) 
 
Oxygen 
Source 
Pivalic 
Acid 
(gm) 
 
Temp 
(°C) 
 
Time 
(hrs) 
 
Conv. 
(%) 
SA-117 0.5 2 ×  25 25 air 3 ×  1 110 2 2 
SA-123 0.5 10 25 O2 4 150 2 2 
SA-124 0.5 25 25 air 2.5 110 2 6 
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Table 4. Alternative Oxygen Sources 
*MW = microwave 
 
Reaction Monitored via Gas Chromatography 
Although 1H NMR was effective at monitoring the progress of the reaction it was not very 
efficient for the high-throughput screening of reactions.   A more time efficient technique was 
needed to monitor the reaction thus allow for faster analysis. To this end, an analysis method  
was developed using gas chromatography. GC parameters are optimized initially by using 
starting material and product mixture. The initial temperature set at 230 °C for 2 mins and 270 
°C for 8 mins. The ramp time set at 15 °C/min. Total operation time is set to be at 12 mins and 
67 sec.  The retention times for first optimized reaction for 2-(3,5-dimethoxyphenoxy)-6-
(trifluoromethyl)-benzonitrile  and  7,9-dimethoxy-2-(trifluoromethyl)dibenzofuran-4-
carbonitrile  are 4.57 and 5.96 respectively. Retention time vs. conversion data for respective 
dibenzofuran is plotted in Figure 11. 
 Table 5 summarizes reaction conditions that were explored using gas chromatographic 
analysis for monitoring the conversion of diaryl ether 1 into dibenzofuran 2. In addition to time 
 
 
 
Entry 
 
1 
(mmol) 
 
Pd(OAc)2 
(mol %) 
 
K2CO3 
(mol%) 
 
 
Oxygen 
Source 
Pivalic 
Acid 
(gm) 
 
 
Temp 
(oC) 
 
 
Time 
(hrs) 
 
 
Conv. 
(%) 
SA-101 0.5 10 10 EtOH 
(0.2 ml) 
0.45 120 72 0 
SA-115 
(MW)* 
0.5 3 ×  25 25 H2O2 
(0.2 mmol) 
3 ×  1.0 120 5 19 
SA-117 
(MW)* 
0.5 20 3 ×  20 Benzoic 
Acid 
(0.75mmol) 
3 ×  1.0 120 2 < 20 
 
 
25 
efficiency, gas chromatography offered the advantage that the reaction could be continuously 
monitored. As illustrated in Figure 8, product formation could be followed in real time. This 
afforded a better sense of how the reaction progressed as well as an indication of when the 
reaction was complete. 
Table 5. Reactions Monitored GC Analysis 
 
As shown in Table 5, gas chromatography analysis was consistent with NMR analysis for 
product formation. Using optimized reaction conditions (entry SA-126), GC analysis gave 
similar results to NMR analysis obtained previously for the same set of conditions (Table 1, 
entry SA-104). Using gas chromatography to evaluate reaction progress, several additional 
experiments were performed. First, the reaction was performed in a 25 ml round bottom flask 
fitted with a condenser to see if minimization of solvent loss accompanied a larger reaction 
 
 
Entry 
 
1 
(mmol) 
 
Catalyst 
(mol %) 
 
K2CO3 
mol% 
 
Oxygen 
Source 
Pivalic 
Acid 
(gm) 
 
Temp 
(oC) 
 
Time 
(hrs) 
 
Conv. 
(%) 
SA-126 0.5 Pd(OAc)2 
(25) 
25 air 1.1 120 144 82 
SA-127 
(RBF 
reflux) 
0.5 Pd(OAc)2 
(25) 
25 air 1.1 120 144 63 
SA-128 0.5 Pd(OAc)2 
(25) 
25 air 1.1 160 44 0 
SA-129 0.5 Pd(OAc)2 
(25)  
(IMes 50 
mol%) 
25 air 2 120 49 7 
SA-131 0.5 Rh2(OAc)4 
(25) 
25 air 1.1 120 24 3 
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surface area would have an effect (entry SA-127).  This experiment demonstrated that 
maintaining solvent levels was critical to the success of the reaction the while importance of 
surface area was less significant. In a second experiment the effect of increased temperature was 
explored. (entry SA-128). In this experiment the temperature was increased to 160 °C. As 
expected, the increase in temperature resulted in decomposition of catalyst and led to low 
conversion of 1 into product. In a third experiment (entry SA-129) the N-heterocyclic carbene 
precusor (IMes•HCl) was added to the reaction mixture. A previous report had suggested that 
this ligand promoted the reaction of palladium catalysts in oxidative ring closure reactions.82 
However, under these reaction conditions, the addition of IMes•HCl did not improve the 
conversion and in fact completely shut down the catalytic reaction. Finally, rhodium (II) acetate 
[Rh2(OAc)4]  (entry SA-13) was explored as a catalyst for the ring closure reaction. However, 
under the optimized conditions established for palladium acetate, rhodium acetate was 
unreactive.   
 
 
Figure 11. Conversion Monitored by Gas Chromatography shows the respective increase in 
product with time for reaction SA-126 and SA-132. 
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Synthesis of Analogues 
After optimizing reaction condition for the formation of 2 (Table 6, SA-126), attempts were 
made to synthesize dibenzofuran analogues. In case of SA-132 maximum conversion was 
observed. Strong electron withdrawing NO2 has a positive effect on product formation by making 
the ring system electron deficient along with activating effect of methoxy (OCH3) on the 
neighboring ring. SA-135 shows low conversion and some peaks of side reaction are also 
observed through GC. Pd insertion in halogenated ring structure could be a possible result of 
observed side reaction peaks. The product was undetermined in case of SA-138 and SA-140 as 
multiple side reaction peaks are observed along with product peaks. As reaction is performed in 
open air, formation of benzoic acid and other related products have been formed. 
Scheme 5.  Synthesis of Dibenzofurans 
Z
Y
X
O
O
O
Pd(OAc)2, (25 mol%)
K2CO3 (25 mol %)
PivOH (1 g), air
144 h, 120 °C
Z
Y
X
O
O
O
1, 3 - 6 2, 7, 8  
 
Table 6:  Synthesis data of dibenzofuran Analogues 
 
 
 
 
 
 
 
 
 
 
*IM = Intractable mixture 
 
Entry 
(diaryl ether) 
 
X 
 
Y 
 
Z 
% Conv. 
(Dibenzofuran) 
 
SA-126 (1) CN CF3 H 83 (2) 
SA-132 (3) H H NO2 97 (7) 
SA-135 (4) Cl H Cl 40 (8) 
SA-138 (5) CN H CHO IM* 
SA-140 (6) H H CHO IM* 
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Conclusion  
 
Various attempts have been made to optimize the synthesis of dibenzofuran via palladium 
catalyzed ring closure reaction. This has been achieved by altering the catalyst and its amount, 
changing oxygen source, changing reaction vial surface area, and using microwave techniques. 
The results of this study show that the synthesis of dibenzofuran via palladium catalyzed 
oxidative ring closure reaction is a very slow reaction. Catalyst loading of 25 mol% of Pd(OAc)2, 
25 mol% K2CO3, pivalic acid as a solvent and air as oxygen source are essential conditions to get 
a dibenzofuran in good yield. In addition, electron-withdrawing groups had a positive effect on 
ring closure and product yield. 
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Future Research 
 
Future research efforts will focus on the synthesis of other dibenzofuran analogues in good yields 
and the development an efficient method for purification of the product. The application of this 
research toward the synthesis of rigid analogues cannabinoid receptor ligands will also be 
pursued. 
Scheme 6. Synthesis of Potential Cannabinoid Agonists 
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Experimental 
2-(3,5-Dimethoxyphenoxy)-6-(trifluoromethyl)-benzonitrile; General Procedure A 
To a solution of 3,5-dimethoxyphenol (3.4 g, 22 mmol), dissolved in NMP (15 mL) was added 
Cs2CO3 (9.8 g, 30 mmol). The mixture was heated under nitrogen at 50°C oil bath for 30 minutes 
to furnish a dark brown phenoxide solution. The aryl fluoride (9.8 g, 30 mmol) in NMP (15 mL) 
was syringed into the solution and the mixture was to stirred at 65 °C for 4 h. The reaction was 
monitored by TLC until the aryl fluoride could no longer be observed.  The reaction mixture was 
allowed to cool to room temperature and then added to H2O (20 mL).  The resulting suspension 
was extracted with toluene (3 x 15 mL).  The combined organic extracts were washed with H2O 
(15mL), brine (15 mL) then dried over MgSO4 and filtered.  The solvent was removed under 
reduced pressure and the residue was triturated with H2O (10 mL), filtered, washed with water 
and then dried under vacuum to afford a shiny white solid; yield: 6.36 g (99 %); mp 95-97 °C. 
1H NMR (CDCl3) δ: 7.57 (t, J = 8.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 
6.36 (s, 1H), 6.25 (s, 2H), 3.78 (s, 6H).  
13C NMR (CDCl3) δ: 162.2, 161.5, 156.1, 134.4, 134.1, 123.8, 121.1, 120.4, 112.6, 100.8, 98.9, 
97.9, 55.7. 
1,3-Dimethoxy-5-(4-nitrophenoxy)benzene 
Prepared according to the general procedure ‘A’ using 3,5-dimethoxyphenol (1.13 g, 7.3mmol) 
Cs2CO3  (3.3 g, 10 mmol), and 1-fluoro-4-nitrobenzene (0.95 g, 6.7 mmol) in NMP (10 mL) at 
65 oC for 2 h. Purification by tituration and filtration afforded a light yellow solid; yield 1.75 g  
1H NMR (CDCl3): δ = 8.20 (d, J = 8.0 Hz, 2 H), 7.05 (d, J = 8.0 Hz, 2 H), 6.34 (t, J = 2.0 Hz, 1 
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H), 6.24 (d, J = 2.0 Hz, 2 H), 3.78 (s, 6H). 
13C NMR (CDCl3): δ = 163.3, 162.2, 156.7, 126.1, 117.5, 115.6, 99.6,	  97.7,	  55.8	  
2,4-Dichloro-1-(3,5-dimethoxyphenoxy)benzene 
Prepared according to general procedure A using 3,5-dimethoxyphenol (3.4 g, 22 mmol), 
Cs2CO3 (9.8 g, 30 mmol), and 2,4-dichloro-1-fluorobenzene (3.3 g, 20 mmol) in NMP (15 mL) 
at 120 °C for 2 h. Purification by flash chromatography (10% EtOAc–hexane) afforded 
a white solid; yield: 5.0 g (84%); mp 44–45 °C. 
1H NMR (CDCl3): δ = 7.48 (d, J = 2.0 Hz, 1 H), 7.19 (dd, J = 8.0, 2.0 Hz, 1 H), 6.96 (d, J = 8.0 
Hz, 1 H), 6.22 (dd, J = 2.0, 2.0 Hz, 1H), 6.10 (t, J = 2.0 Hz, 2 H), 3.74 (s, 6 H). 
13C NMR (CDCl3): δ = 161.9, 158.7, 151.2, 130.7, 129.7, 128.3, 127.0, 122.1, 96.7, 96.0, 55.7. 
2-(3,5-dimethoxyphenoxy)-5-formylbenzonitrile 
Prepared according to the general Procedure A using 3,5-dimethoxyphenol (1.13, 7.3mmol), 
Cs2CO3 (3.26g, 10mmol), and  3-fluoro-5-formylbenzonitrile (1g, 6.7mmol) in NMP (10 mL) at 
50 °C for  1h and then 35 °C for 21 h. General procedure A was followed for purification, 
afforded a tangerine solid; yield: 1.72g (91%). 
1H NMR (CDCl3): δ: 9.98 (s, 1H), 8.30 (s, 1H), 8.23 (d, 2H), 7.51 (d, 2H), 6.29 (s, 2H), 6.09 (s, 
1H), 3.83 (s, 6H). 
13C NMR (CDCl3):	  δ = 191.0, 165.4, 160.2, 160.1, 132.8, 135.3, 130.7, 118.7, 115.8, 104.9, 95.9, 
93.5, 55.8. 
 
4-(3,5-Dimethoxyphenoxy)benzaldehyde 
Prepared according to the general procedure A using using 3,5-dimethoxyphenol (1.13, 7.3 
mmol), Cs2CO3 (3.26g, 10mmol), 4-fluorobenzaldehyde (0.83g, 6.7 mmol), in 10 mL of NMP at 
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60 oC for 3 h. General purification procedure A is followed and by column chromatography  
(20% EtOAc/Hexane)  afforded a white solid; yield: 1.1g (64%). 
1H NMR (CDCl3): δ: 9.98 (s, 1H), 7.95 (d, 2H), 7.33(d, 2H), 6.29 (s, 2H), 6.09 (s, 1H), 3.83 (s, 
6H). 
13C NMR (CDCl3): δ = 191.0, 162.8, 160.2, 160.1, 131.0, 130.0, 118.0, 95.9, 93.5, 55.8  
 
General Procedure B for intramolecular Pd(II)-catalyzed oxidative ring closure reaction.  
In a typical reaction the diaryl compound (0.5 mmol), Pd(OAc)2  (25 mol%), K2CO3 (25 mol%) 
and pivalic acid (1100 mg) was added to a 10 ml reaction tube. The uncapped  tube was placed in 
an oil bath and the mixture was stirred at a set temperature over a specified time. The reaction 
was monitored by NMR or gas chromatography. The solution was then cooled to room 
temperature, diluted with dichloromethane (10 ml), washed with saturated aqueous solution of 
Na2CO3, dried over Na2SO4, filtered and evaporated under reduced pressure. The crude product 
was purified by silica gel chromatography or Prep TLC to afford the corresponding 
dibenzofuran.  
7,9-Dimethoxy-2-(trifluoromethyl)dibenzofuran-4-carbonitrile 
Prepared according to general procedure B using 2-(3,5-Dimethoxyphenoxy)-6-
(trifluoromethyl)-benzonitrile (0.16g, 0.5 mmol), Pd(OAc)2 (0.028g, 0.125 mmol), K2CO3  
(0.017, 0.125 mmol) in 1.2 g of pivalic acid. The product is purified via column chromatography, 
to afford a white solid; yield (82%). 
1H NMR (CDCl3): δ: 8.22 (d, 2H), 7.68 (d, 2H), 6.82 (d, 1H), 6.48 (s. 1H), 3.93 (s, 3H), 3.78 (s, 
3H). 
13C NMR (CDCl3): δ = 159.7, 158.5, 150.9, 145.0, 126.4, 124.9, 123.9, 120.6, 115.8, 113.4, 
106.4, 96.1, 88.6, 87.8, 56.1, 55.8. 
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1,3-Dimethoxy-8-nitrodibenzofuran 
Prepared according to general procedure B using 2-(3,5-Dimethoxyphenoxy)-6-
(trifluoromethyl)-benzonitrile (0.14g, 0.5 mmol), Pd(OAc)2 (0.028g, 0.125 mmol), K2CO3  
(0.017, 0.125 mmol) in 1.2 g of Pivalic Acid. The product was purified via prep plate thin layer 
chromatography to afford a yellowish solid; yield (97%). 
1H NMR (CDCl3): δ: 8.86 (d, 1H), 8.27 (q, 2H), 7.54 (d, 2H), 6.74 (d, 1H), 6.47 (d, 1H), 4.05 (s, 
3H), 3.85 (s, 1H). 
13C NMR (CDCl3): δ = 162.6, 159.7,150.9, 146.0,145.9, 128.3, 120.2, 116.7, 114.5, 112.4, 88.6,  
87.8,  56.1, 55.8. 
 
6,8-Dichloro-1, 3-dimethoxydibenzofuran 
Prepared according to general procedure B using 2-(3,5-Dimethoxyphenoxy)-6-
(trifluoromethyl)-benzonitrile (0.15g, 0.5 mmol), Pd(OAc)2 (0.028g, 0.125 mmol), K2CO3  
(0.017, 0.125 mmol) in 1.2 g of pivalic acid. The product was purified via column 
chromatography to afford a white solid; yield (40%). 
1H NMR (CDCl3): δ : 7.39 (d, 1H), 7.21 (d, 1H), 6.78 (s, 1H), 6.15 (d, 1H), 3.83 (s, 3H), 3.83 (s, 
3H). 
 
13C NMR (CDCl3): δ = 159.7, 158.5, 150.9, 145.0, 130.1, 118.5 113.4, 111.1, 106.4, 88.6, 87.8, 
56.1, 55.8. 
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2-Formyl-7, 9-dimethoxydibenzofuran-4-carbonitrile 
Prepared according to general procedure B using 2-(3,5-Dimethoxyphenoxy)-6-
(trifluoromethyl)-benzonitrile (0.14g, 0.5 mmol), Pd(OAc)2 (0.028g, 0.125 mmol), K2CO3  
(0.017, 0.125 mmol) in 1.2 g of pivalic acid. TLC and NMR data showed an intractable mixture 
of products. 
7,9-Dimethoxydibenzofuran-2-carbaldehyde 
Prepared according to general procedure B using 2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)-
benzonitrile (0.13g, 0.5 mmol), Pd(OAc)2 (0.028g, 0.125 mmol), K2CO3  (0.017, 0.125 mmol) in 
1.2 g of pivalic acid. TLC and NMR data show intractable mixture of products. 
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